Regulation of Amphiregulin Gene Expression by β-Catenin Signaling in Human Hepatocellular Carcinoma Cells: A Novel Crosstalk between FGF19 and the EGFR System

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Latasa, Maria U ^a   Salis, Fabiana ^b   Urtasun, Raquel ^a   Garcia Irigoyen, Oihane ^a   Elizalde, Maria ^a   Uriarte, Iker ^c   Santamaria, Monica ^a   Feo, Francesco ^b   Pascale, Rosa M ^b   Prieto, Jesús ^a,c   Berasain, Carmen ^a,c   Avila, Matías A ^a,c  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF SASSARI   (Italy)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIREGULIN; BETA CATENIN; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR 19; MUTANT PROTEIN;

ARTICLE; CANCER TISSUE; CARCINOMA CELL; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; GENE ACTIVATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MOLECULAR INTERACTION; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; UPREGULATION;

BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; BETA CATENIN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; MUTATION; PROGNOSIS; PROMOTER REGIONS, GENETIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84871432729     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052711     Document Type: Article

References (69)

1. Llovet JM, Burroughs A, Bruix J, (2003) Hepatocellular carcinoma. Lancet 362: 1907-1917.
2. El-Serag HB, Rudolph KL, (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576.
3. Bosch FX, Ribes J, Diaz M, Cleries R, (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterology 127: S5-S16.
4. El-Serag HB, (2004) Hepatolcellular carcinoma: recent trends in the United States. Gastroenterology 127: S27-S34.
5. Baffy G, Brunt EM, Caldwell SH, (2012) Hepatocellular carcinoma in non-alcoholic fatty liver disease: An emerging menace. J Hepatol 56: 1384-1391.
6. Sherman M, Bruix J, (2011) Management of hepatocellular carcinoma: an update. Hepatology 53: 1020-1022.
7. Villanueva A, Llovet JM, (2011) Targeted therapies for hepatocellular carcinoma. Gastroenterology 140: 1410-1426.
8. Forner A, Llovet JM, Bruix J, (2012) Hepatocellular carcinoma. Lancet 379: 1245-1255.
9. Lee JS, Thorgerisson SS, (2006) Comparative and integrative functional genomics of hepatocellular carcinoma. Oncogene 25: 3801-3809.
10. Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B, et al. (2010) Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis 30: 35-51.
11. Nault JC, Zucman-Rossi J, (2011) Genetics of hepatobiliary carcinogenesis. Semin Liver Dis 31: 173-187.
12. Avila MA, Berasain C, Sangro B, Prieto J, (2006) New therapies for hepatocellular carcinoma. Oncogene 25: 3866-3884.
13. Breuhahn K, Schirmacher P, (2010) Signaling networks in human hepatocarcinogenesis. Novel aspects and therapeutic options. Prog Mol Biol Transl Sci 97: 251-277.
14. Whittaker S, Marais R, Zhu AX, (2010) The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 29: 4989-5005.
15. Calvisi D, Frau M, Tomasi ML, Feo F, Pascale RM, (2012) Deregulation of signaling pathways in prognostic subtypes of hepatocellular carcinoma: Novel insights from interspecies comparison. Biochim Biophys Acta 1826: 215-237.
16. Villanueva A, Llovet JM, (2012) Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib. Clin Cancer Res 18: 1824-1826.
17. Berasain C, Castillo J, Prieto J, Avila MA, (2007) New molecular targets for hepatocellular carcinoma: the ErbB1 signalling system. Liver Int 27: 174-185.
18. Berasain C, Latasa MU, Urtasun R, Goñi S, Elizalde M, et al. (2011) Epidermal growth factor receptor (EGFR) corsstalks in liver cancer. Cancers 3: 2444-2461.
19. Urtasun R, Latasa MU, Demartis MI, Balzani S, Goñi S, et al. (2011) Connective tissue growth factor autocriny in human hepatocellular carcinoma: oncogenic role and regulation by epidermal growth factor receptor/yes-associated protein-mediated activation. Hepatology 54: 2149-2158.
20. Castillo J, Erroba E, Perugorria MJ, Santamaria M, Lee DC, et al. (2006) Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells. Cancer Res 66: 6129-6138.
21. Desbois-Mouthon C, Cacheux W, Blivet-Van Eggelpoël MJ, Barbu V, Fartoux L, et al. (2006) Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib. Int J Cancer 119: 2557-2566.
22. Castillo J, Goñi S, Latasa MU, Perugorria MJ, Calvo A, et al. (2009) Amphiregulin induces the alternative splicing of p73 into its oncogenic isoform DeltaExp73 in human hepatocellular tumors. Gastroenterology 137: 1805-1815.
23. Busser B, Sancey L, Brambilla E, Coll JL, Hurbin A, (2011) The multiple roles of amphiregulin in human cancer. Biochim Biophys Acta 1816: 119-131.
24. Ezzoukhry Z, Louandre C, Trécherel E, Godin C, Chauffert B, et al. (2012) EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib. Int J Cancer (Epub ahead of print).
25. Blivet-Van Eggelpoël MJ, Chettouh H, Fartoux L, Aoudjehane L, Rey C, et al. (2012) Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells. J Hepatol 57: 108-115.
26. Dahmanin R, Just PA, Perret C, (2011) The Wnt/β-catenin pathway as a therapeutic target in human hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 35: 709-713.
27. Bengochea A, de Souza MM, Lefrançois L, Le Roux E, Galy O, et al. (2008) Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma. Brit J Cancer 99: 143-150.
28. Civenni G, Holbro T, Hynes NE, (2003) Wnt1 and Wnt5a induce cyclin D1 expression through ErbB1 transactivation in HC11 mammary epithelial cells. EMBO Reports 4: 166-171.
29. Lu Z, Ghosh S, Wang Z, Hunter T, (2003) Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of β-catenin, and enhanced tumor cell invasion. Cancer Cell 4: 499-515.
30. Tan X, Apte U, Micsenyi A, Kotsagrelos E, Luo JH, et al. (2005) Epidermal growth factor receptor: a novel target of the Wnt/β-catenin pathway in liver. Gastroenterology 129: 285-302.
31. Torre C, Benhamouche S, Mitchell C, Godard C, Veber P, et al. (2012) The transforming growth factor-α and cyclin D1 genes are direct targets of β-catenin signalling in hepatocyte proliferation. J Hepatol 55: 86-95.
32. Sawey ET, Chanrion M, Cai C, Wu G, Zhang J, et al. (2011) Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening. Cancer Cell 19: 347-358.
33. Pai R, Dunlap D, Qing J, Mohtashemi I, Hotzel K, et al. (2008) Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating β-catenin signalling. Cancer Res 68: 5086-5095.
34. Pardo-Saganta A, Latasa MU, Castillo J, Alvarez-Asiain L, Perugorria MJ, et al. (2009) The EGFR ligand amphiregulin is a negative regulator of hepatic acute phase gene expression. J Hepatol 51: 1010-1020.
35. Plowman GD, Green J, McDonald VL, Neubauer MG, Disteche CM, et al. (1989) The amphiregulin gene encodes a novel epidermal growth factor-related protein with tumor-inhibitory activity. Mol Cell Biol 10: 1969-1981.
36. Renard CA, Labalette C, Armengol C, Cougot D, Wei Y, et al. (2007) Tbx3 is a downstream target of the Wnt/β-catenin pathway and a critical mediator of β-catenin survival functions in liver cancer. Cancer Res 67: 901-910.
37. Berasain C, Hevia H, Fernández-Irigoyen J, Larrea E, Caballería J, et al. (2004) Methylthioadenosine phosphorylase gene expresión is impaired in human liver cirrhosis and hepatocarcinoma. Biochim Biophys Acta 1690: 276-284.
38. Perugorria MJ, Latasa MU, Nicou A, Cartagena-Lirola H, Castillo J, et al. (2008) The epidermal growth factor receptor ligand amphiregulin participates in the development of mouse liver fibrosis. Hepatology 48: 1251-1261.
39. Katoh Y, Katoh M, (2006) Canonical WNT signalling pathway and human AREG. Int J Mol Med 17: 1163-1166.
40. Gschwind A, Hart S, Fischer OM, Ullrich A, (2003) TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells. EMBO J 22: 2411-2421.
41. Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, et al. (2006) A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 12: 410-416.
42. Jia HL, Ye QH, Qin LX, Budhu A, Forgues M, et al. (2007) Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma. Clin Cancer Res 13: 1133-1139.
43. Stambolic V, Ruel L, Woodgett JR, (1996) Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 6: 1664-1668.
44. Coghlan MP, Culbert AA, Cross DA, Corcoran SL, Yates JW, et al. (2000) Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene expression. Chem Biol 7: 793-803.
45. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R, (1997) Betacatenin is a target for the ubiquitin-proteasome pathway. EMBO J 16: 3797-3804.
46. MacDonald BT, Tamai K, He X, (2009) Wnt/beta-catenin signalling: components, mechanisms, and diseases. Dev Cell 17: 9-26.
47. White BD, Chien AJ, Dawson DW, (2012) Dysregulation of Wnt/β-catenin signalling in gastrointestinal cancers. Gastroenterology 142: 219-232.
48. Wei Y, Fabre M, Branchereau S, Gauthier F, Perilongo G, et al. (2000) Activation of β-catenin in epithelial and mesenchymal hepatoblastomas. Oncogene 19: 498-505.
49. Merle P, de la Monte S, Kim M, Herrmann M, Tanaka S, et al. (2004) Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. Gastroenterology 127: 1110-1122.
50. Zeng G, Apte U, Cieply B, Singh S, Monga SP, (2007) siRNA-mediated beta-catenin knockdown in human hepatoma cells results in decreased growth and survival. Neoplasia 9: 951-959.
51. Wege H, Heim D, Lütgehetmann M, Dierlamm J, Lohse AW, et al. (2011) Forced activation of β-catenin signaling supports the transformation of hTERT-immortalized human fetal hepatocytes. Mol Cancer Res 9: 1222-1231.
52. Desbois-Mouthon C, Cadoret A, Blivet-Van Eggelpoël MJ, Bertrand F, Cherqui G, et al. (2001) Insulin and IGF-1 stimulate the β-catenin pathway through two signalling cascades involving GSK-3b inhibition and Ras activation. Oncogene 20: 252-259.
53. Hoshida Y, Nijman SBM, Kobayashi M, Chan JA, Brunet JP, et al. (2009) Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 69: 7385-7392.
54. Yang W, Xia Y, Ji H, Zheng Y, Liang J, et al. (2011) Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation. Nature 480: 118.122.
55. Yuzugullu H, Benhaj K, Ozturk N, Senturk S, Celik E, et al. (2009) Canonical Wnt signalling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma. Mol Cancer 8: 90.
56. Desnoyers LR, Pai R, Ferrando RE, Hötzel K, Le T, et al. (2008) Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene 27: 85-97.
57. Miura S, Mitsuhashi N, Shimizu H, Kimura F, Yoshidome H, et al. (2012) Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma. BMC Cancer 12: 56.
58. Berasain C, Castillo J, Perugorria MJ, Prieto J, Avila MA, (2007) Amphiregulin: a new growth factor in hepatocarcinogenesis. Cancer Lett 254: 30-41.
59. Vivanco I, Mellinghoff IK, (2010) Epidermal growth factor receptor inhibitors in oncology. Curr Opin in Oncol 22: 573-578.
60. Miyamoto S, Fukami T, Yagi H, Kuroki M, Yotsumoto F, (2009) Potential for molecularly targeted therapy against epidermal growth factor receptor ligands. Anticancer Res 29: 823-830.
61. Nejak-Bowen KN, Monga SPS, (2011) Beta-catenin signalling, liver regeneration and hepatocellular cancer: sorting the good from the bad. Seminars in Cancer Biology 21: 44-58.
62. Hu T, Li C, (2010) Convergence between Wnt-β-catenin and EGFR signalling in cancer. Mol Cancer 9: 236.
63. Schlange T, Matsuda Y, Lienhard S, Huber A, Hynes NE, (2007) Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation. Breast Cancer Res 9: R63.
64. Baillo A, Giroux C, Ethier SP, (2011) Knock-down of amphiregulin inhibits cellular invasion in inflammatory breast cancer. J Cell Physiol 226: 2691-2701.
65. Monga SP, Mars WM, Pediaditakis P, Bell A, Mulé K, et al. (2002) Hepatocyte growth factor induces Wnt-independent nuclear translocation of beta-catenin after Met-beta-catenin dissociation in hepatocytes. Cancer Res 62: 2064-2071.
66. Bade LK, Goldberg JE, DeHut HA, Hall MK, Schwertfeger KL, (2011) Mammary tumorigenesis induced by fibroblast growth factor receptor 1 requires activation of the epidermal grwoth factor receptor. J Cell Sci 124: 3106-3117.
67. Gauglhofer C, Sagmeister S, Schrottmaier W, Fischer C, Rodgarkia-Dara C, et al. (2011) Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis. Hepatology 53: 854-864.
68. Poh W, Wong W, Ong H, Aung MO, Lim SG, et al. (2012) Klotho-beta overexpression as a novel target for suppressing proliferation and fibroblast growth factor receptor-4 signaling in hepatocellular carcinoma. Mol Cancer 11: 14.
69. French DM, Lin BC, Wang M, Adams C, Shek T, et al. (2012) Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PLoS One 7(5): e36713.